Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics

Cancer Letters

Volumn 330, Issue 1, 2013, Pages 57-66

  Panis, Carolina ^a,b   Pizzatti, Luciana ^a   Herrera, Ana Cristina ^b,c   Cecchini, Rubens ^b   Abdelhay, Eliana ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b STATE UNIVERSITY OF LONDRINA   (Brazil)

^c Hospital do Câncer de Londrina   (Brazil)

Author keywords

Breast cancer; Circulating markers; High throughput proteomics

Indexed keywords

BIOLOGICAL MARKER; CLUSTERIN; GELSOLIN; GRAINY HEAD LIKE 3 PROTEIN; LUMICAN; MISMATCH REPAIR PROTEIN PMS2; SAL LIKE PROTEIN 4; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER GROWTH; CANCER STAGING; COMPUTER ANALYSIS; CONTROLLED STUDY; EARLY CANCER; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872836488     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.020     Document Type: Article

References (53)

1. Bombonati A., Sgroi D.C. The molecular pathology of breast cancer progression. J. Pathol. 2011, 223:307-317.
2. Klein C.A. Parallel progression of primary tumours and metastasis. Nature 2009, 9:302-312.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Panis C., Victorino V.J., Herrera A.C.S.A., Freitas L.F., deRossi T., Campos F.C., Colado Simão N.A., et al. Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res. Treat. 2011, 10.1007/s10549-011-1851-1.
5. DeNardo D.G., Coussens L.M. Balancing immune response: crosstalk between adaptative and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9:212.
6. Schorey J.S., Bhatnagar S. Exosome function: from tumor immunology to pathogen biology. Traffic 2008, 9:871-881.
7. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings on a new thoughts. Semin. Cancer Biol. 2011, 21:139-146.
8. Winden A.W.J.O., Krop E.J.M., Karedal M.H., Gats M.C.W., Lindh C.H., Jeppson M.C., et al. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagniostic serum; a nested case-control study. BMC Cancer 2011, 11:381.
9. Patz E.F., Campa M.J., Gottlin E.B., Kusmartseva I., Guan X.R., Herndon J.E. Panel of serum biomarkers for the diagnosis of lung cancer. J. Clin. Oncol. 2007, 25:5578-5583.
10. Findeisen P., Zapatka M., Peccerella T., Matzk H., Neumaier M., Schadendorf D., Ugurel S. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profile. J. Clin. Oncol. 2009, 27:2199-2208.
11. Breuer E.K.Y., Murph M.M. The role of proteomics in the diagnosis and treatment of women's cancers: current trends in technology and future opportunities. Int. J. Proteom. 2011, 10.1155/2011/373584.
12. Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res. 2012, 10.1158/0008-5472.CAN-11-3711.
13. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., Somerfield M.R., Hayes D.F., Bast R.C. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25:5287-5312.
14. Levin Y., Jaros J.A., Schwars E., Bahn S. Multidimensional protein fractionation of blood proteins coupled to data-independent nano-LC-MS/MS analysis. J. Proteom. 2010, 73(3):689-695.
15. Krishmamurthy D., Levin Y., Harris L.W., Umrania Y., et al. Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. Proteomics 2011, 11(3):495-500.
16. L. Pizzatti, C. Panis, G. Lemos, M. Rocha, R. Cecchini, G.H.M.F. Souza, E. Abdelhay, Label-free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance. Proteomics (2012). doi:10.1002/pmic.201200066.
17. Mc Shane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2005, 2(8):416-422.
18. Collins T.J. Image J for microscopy. BioTechniques 2007, 43:S25-S30.
19. Silva J.C., Denny R., Dorschel C.A., Gorenstein M., et al. Quantitative proteomic analysis by accurate mass retention time pairs. Anal. Chem. 2005, 77(7):2187-2200.
20. E) in simple and complex samples: a systematic evaluation. Proteomics 2011, 11:3273-3287.
21. Ting S.B., Caddy J., Hislop N., Vilanowski T., Auden A., Zhao L., Ellis S., Kaur P., Uchida Y., Holleran W.M., Elias P.M., Cunningham J.M., Jane S.M. A homolog of drosophila grainy head is essential for epidermal integrity in mice. Science 2005, 308:411-413.
22. Seifert J.R.K., Mlodzik M. Frizzled/PCP signaling: a conserved mechanism regulating cell polarity and direct motility. Nat. Rev. Gen. 2007, 8:126-138.
23. Morrinson S.J., Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006, 441:1068-1074.
24. Aguila J.R., Liao W., Yang J., Avila C., Hagag N., Senzel L., Ma Y. SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. Blood 2011, 118(3):576-585.
25. Kobayashi D., Kuribayshi K., Tanaka M., Watanabe N. SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. Int. J. Oncol. 2011, 38(4):933-939.
26. Van den Berg D.L., Snoek T., Mullin N.P., Yates A., Bezstarosti K., Demmers J., Chambers I., Poot R.A. An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell 2010, 6(4):369-381.
27. Gao C., Kong N.R., Chai L. The role of stem cell factor SALL4 in leukemogenesis. Crit. Rev. Oncogen. 2011, 16(1-2):117-127.
28. Yang J., Chai L., Gao C., Fowles T.C., Alipio Z., Dang H., et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood 2008, 112:805-813.
29. Kim J.J., Lee S.B., Park J.K., Yoo Y.D. TNF- α induced ROS production triggering apoptosis is directly linked to Romo1 and Bcl-XL. Cell Death Diff. 2010, 17:1420-1434.
30. Shen H.M., Pervaiz S. TNF receptor superfamily-induced cell death: redox dependent execution. Faseb J. 2006, 20:1589-1598.
31. Chintamani Jha B.P., Bhandari V., Bansal A., Saxena S., Bhatnagar D. The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer. Int. Semin. Surg. Oncol. 2007, 4:5.
32. Son B.H., Ahn S.H., Ko C.D., Ka I.W., Gong G.Y., Kim J.C. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J. 2004, 10(1):20-26.
33. Kang X., Chen W., Kim R.H., Kang M.K., Park N.H. Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells. Oncogene 2009, 28(4):565-574.
34. Sun H.Q., Yamamoto M., Mejillano M., Yin H.L. Gelsolin, a multifunctional actin regulatory protein. J. Biol. Chem. 1999, 274(47):33179-33182.
35. Van den Abbeele A., De Corte V., Van Impe K., Bruyneel E., Boucherie C., Bracke M., et al. Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett. 2007, 255(1):57-70.
36. Li Q., Ye Z., Wen J., Ma L., He Y., Lian G., Wang Z., Wei L., Wu D., Jiang B. Gelsolin, but not its cleavage, is required for TNF-induced ROS generation and apoptosis in MCF-7 cells. Biochem. Biophys. Res. Commun. 2009, 385(2):284-289.
37. Seya T., Tanaka N., Shinji S., Yokoi K., Koizumi M., Teranishi N., Yamashita K., Tajiri T., Ishiwata T., Naito Z. Lumican expression in advanced colorectal cancer with nodal metastasis correlatos with poor prognosis. Oncol. Rep. 2006, 16(6):1225-1230.
38. Matsuda Y., Yamamoto T., Kudo M., Kawahara K., Kawamoto M., Nakajima Y., Koizumi K., Nakazawa N., Ishiwata T., Naito Z. Expression and roles of lumican in luna adenocarcinoma and squamous cell carcinoma. Int. J. Oncol. 2008, 33(6):1177-1185.
39. Brezillon S., Venteo L., Ramona L., D'Onofrio M.F., Perreau C., Pluot M., Maquart F.X., Wegrowski Y. Expression of lumican, a small leucine-rich proteoglycan with antitumor activity, in human malignant melanoma. Clin. Exp. Dermatol. 2007, 32(4):405-416.
40. Zeltz C., Brezillon S., Kapyla J., Eble J.A., Bobichon H., Terryn C., Perreau C., Franz C.M., Heino J., Maquart F.X., Wegrowski Y. Lumican inhibits cell migration through α2β1 integrin. Exp. Cell Res. 2010, 316(17):2922-2931.
41. Devauchelle V., Essabbani A., De Pinieux G., Germain S., Toruneur L., Mistou S., et al. Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. J. Immunol. 2006, 177:6471-6479.
42. Prats C., Cadefau J.A., Cussó R., Qvortrup K., Nielsen J.N., Wojtaszewski J.F.P., et al. Phosphorylation-dependent translocation of glycogen synthase to a novel structure during glycogen resynthesis. J. Biol. Chem. 2005, 280:23165-23172.
43. Yu Z., Lin K.K., Bhandari A., Spencer J.A., Xu X., Wang N., et al. The grainyhead-like epithelial transactivator Get-1/GRHL3 regulates epidermal terminal differentiation and interacts functionally with LMO4. Dev. Biol. 2006, 299:122-136.
44. Schroers R., Huang X.F., Hammer J., Zhang J., Chen S.Y. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T helper cells. Cancer Res. 2002, 62:2600-2605.
45. Li L.F., Chen B.X., Tsai Y.H., Kao W.W.Y., Yang C.T., et al. Lumican expression in diaphragm induced by mechanical ventilation. PLoS ONE 2011, 6(9):e24692.
46. Nakagawa H., Lockman J.C., Frankel W.L., Hampel H., Steenblock K., Burgart L.J., et al. Mismatch-repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res. 2004, 64(14):4721-4727.
47. Li H., Xu D., Li J., Berndt M.C., Liu J.P. Transforming growth factor beta suppresses human telomerase reverse trascriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J. Biol. Chem. 2006, 281(35):25588-25600.
48. Di Tomaso T., Mazzoleni S., Wang E., Sovena G., Clavenna D., Franzin A., et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 2010, 16:800-813.
49. Schroers R., Shen L., Rollins L., Rooney C.M., Slawin K., Sonderstrup G., et al. Human telomerase reverse transcriptase-specific T helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin. Cancer Res. 2003, 15:4743-4755.
50. Hochreiter A.E., Xiao H., Goldblatt E.M., Gryaznov S.G., Miller K.D., Badve S., Sledge G.W., Herbert B.S. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin. Cancer Res. 2012, 12:3184-3192.
51. Kirkpatrick K.L., Ogunkolade W., Elkaka A.E., Bustin S., Jenkins P., Ghilchik M., Newbold R.F., Mokbel K. HTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumor stage and c-Myc expression. Breast Cancer Res. Treat. 2003, 77(3):277-284.
52. Bednarek A.K., Sahin A., Brenner A.J., Johnston D.A., Aldaz C.M. Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast acrcinoma stage. Clin. Cancer Res. 1997, 3(1):6-11.
53. Tsao J.I., Zhao Y., Lukas J., Yang X., Shah A., Press M., Shibata D. Telomerase activity in normal and neoplastic breast. Clin. Cancer Res. 1997, 3:627-631.